Holen Sie sich die Stockscreener-App
10.43
3.17%
0.32
Handel nachbörslich:
10.23
-0.20
-1.92%
Schlusskurs vom Vortag:
$10.11
Offen:
$10.2
24-Stunden-Volumen:
24,090
Relative Volume:
0.27
Marktkapitalisierung:
$68.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.48M
KGV:
-10.03
EPS:
-1.04
Netto-Cashflow:
$-28.71M
1W Leistung:
+10.37%
1M Leistung:
-28.85%
6M Leistung:
-34.77%
1J Leistung:
-29.88%
1-Tages-Spanne:
$10.20
$10.43
1-Wochen-Bereich:
$9.23
$10.70
52-Wochen-Spanne:
$4.11
$28.68
Forte Biosciences Inc Stock (FBRX) Company Profile
Firmenname
Forte Biosciences Inc
Sektor
Branche
Telefon
(310) 618-6994
Adresse
3060 PEGASUS PARK DRIVE, DALLAS, CA
Vergleichen Sie FBRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
10.43 | 115.42M | 0 | -31.48M | -28.71M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-21 | Eingeleitet | TD Cowen | Buy |
| 2024-04-08 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-09-20 | Hochstufung | Chardan Capital Markets | Sell → Buy |
| 2021-09-03 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-09-03 | Herabstufung | Chardan Capital Markets | Buy → Sell |
| 2021-09-03 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2021-09-03 | Herabstufung | Truist | Buy → Hold |
| 2021-05-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-03-26 | Eingeleitet | Citigroup | Buy |
| 2020-08-28 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-08-25 | Eingeleitet | Truist | Buy |
Alle ansehen
Forte Biosciences Inc Aktie (FBRX) Neueste Nachrichten
What drives Forte Biosciences Inc. stock priceFree Investment Community - jammulinksnews.com
Is Forte Biosciences Inc. a good long term investmentFree Bull & Bear Market Updates - Autocar Professional
What analysts say about Forte Biosciences Inc. stockRapid growth trajectories - jammulinksnews.com
How the (FBRX) price action is used to our Advantage - news.stocktradersdaily.com
What makes Forte Biosciences Inc. stock price move sharplyDaily Swing Candidates - Newser
Forte Biosciences Inc. Stock Analysis and ForecastGame-changing capital returns - jammulinksnews.com
WVVI Stock Analysis and ForecastFree Bull & Bear Market Updates - Jammu Links News
Why Forte Biosciences Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - Newser
How Forte Biosciences Inc. stock performs during market volatilityTop Momentum Stock Pick - Newser
Forte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX) - Defense World
Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates - insights.citeline.com
Forte Biosciences (FBRX): A Strategic Buy in Biotech's High-Reward Arena - AInvest
individual investors who own 54% along with institutions invested in Forte Biosciences, Inc. (NASDAQ:FBRX) saw increase in their holdings value last week - Yahoo Finance
(FBRX) Investment Analysis and Advice - news.stocktradersdaily.com
Forte Biosciences, Inc.(NasdaqCM: FBRX) added to Russell 3000E Index - MarketScreener
FBRX SEC FilingsForte Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Stock Sell-Offs Trigger Market Turmoil For Firms - Finimize
Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX) - Defense World
Firm Advises Forte Biosciences on $75 Million Public Offering - Wilson Sonsini
Forte Biosciences (FBRX) Plans $75 Million Public Offering - GuruFocus
Forte Biosciences Announces Public Offering of Shares - TipRanks
Forte Biosciences Announces Proposed Public Offering - FinancialContent
Forte’s celiac disease drug shows positive results in Phase 1b trial - Investing.com Nigeria
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study - New Castle News
Forte Biosciences (FBRX) Soars 16.75% on Positive Clinical Trial Results - AInvest
Valkyrie Balance Sheet Opportunities ETF (NYSEARCA:VBB) Trading 0.4% Higher – Here’s Why - Defense World
Traders Buy Large Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - Defense World
With Forte Biosciences Up 28%, Insider Buyers Count Their Returns - simplywall.st
(FBRX) Long Term Investment Analysis - news.stocktradersdaily.com
Forte Biosciences (FBRX) Receives Buy Rating as FB-102 Shows Blockbuster Potential | FBRX Stock News - GuruFocus
Forte Biosciences reports annual meeting results By Investing.com - Investing.com Nigeria
Forte Biosciences reports annual meeting results - Investing.com
Forte Biosciences Elects New Directors at Annual Meeting - TipRanks
Finanzdaten der Forte Biosciences Inc-Aktie (FBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):